Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. (Q47920560)
Jump to navigation
Jump to search
scientific article published on 12 April 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. |
scientific article published on 12 April 2017 |
Statements
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment (English)
K Haratani
H Hayashi
T Tanaka
H Kaneda
Y Togashi
K Sakai
K Hayashi
S Tomida
Y Chiba
K Yonesaka
Y Nonagase
T Takahama
J Tanizaki
K Tanaka
T Yoshida
M Takeda
H Yoshioka
T Ishida
T Mitsudomi
K Nishio
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference